Log in

BioMerieux Stock Forecast, Price & News

+1.20 (+0.81 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $149.65
50-Day Range
MA: $153.28
52-Week Range
Now: $149.65
Volume1 shs
Average Volume493 shs
Market Capitalization$17.71 billion
P/E Ratio58.00
Dividend YieldN/A
bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test based on biomarkers, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is based in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Read More
BioMerieux logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Private households



Sales & Book Value

Annual Sales$3.00 billion
Cash Flow$4.37 per share
Book Value$21.33 per share



Market Cap$17.71 billion
Next Earnings DateN/A
OptionableNot Optionable
+1.20 (+0.81 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMXMF News and Ratings via Email

Sign-up to receive the latest news and ratings for BMXMF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BioMerieux (OTCMKTS:BMXMF) Frequently Asked Questions

How has BioMerieux's stock been impacted by Coronavirus?

BioMerieux's stock was trading at $91.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BMXMF shares have increased by 63.6% and is now trading at $149.65.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of BioMerieux?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMerieux in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for BioMerieux

Who are some of BioMerieux's key competitors?

Who are BioMerieux's key executives?

BioMerieux's management team includes the following people:
  • Mr. Alexandre Mérieux, Chairman & CEO (Age 45)
  • Mr. Guillaume Bouhours, Exec. VP and Exec. VP of Fin., Purchasing & Information Systems (Age 43)
  • Sylvain Morgeau, Investor Relations
  • Ms. Valérie Leyldé, Exec. VP of HR and Communications
  • Mr. Michel Baguenault, Exec. VP & Company Sec.

What is BioMerieux's stock symbol?

BioMerieux trades on the OTCMKTS under the ticker symbol "BMXMF."

How do I buy shares of BioMerieux?

Shares of BMXMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioMerieux's stock price today?

One share of BMXMF stock can currently be purchased for approximately $149.65.

How big of a company is BioMerieux?

BioMerieux has a market capitalization of $17.71 billion and generates $3.00 billion in revenue each year. The company earns $305.54 million in net income (profit) each year or $2.58 on an earnings per share basis. BioMerieux employs 12,000 workers across the globe.

What is BioMerieux's official website?

The official website for BioMerieux is www.biomerieux.com.

How can I contact BioMerieux?

BioMerieux's mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The company can be reached via phone at 33-4-78-87-20-00 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.